It looks like the CHMP, Europe's version of the FDA advisory committee, didn't want the month to end without two big positive opinions, giving investors a nice little present heading into the weekend. Celgene's (NASDAQ: CELG ) relapsed and refractory multiple myeloma drug pomalidomide, and Aegerion's (NASDAQ: AEGR ) HoFH drug Juxtapid, are now likely to be approved in the EU.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion and Celgene, along with their competitors.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.